Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall—has no relevant financial relationships to disclose in relation to the content of this activity.
Ursula Matulonis, MD—has disclosed that she is a consultant for 2X Oncology, FUJIFILM, Geneos, Immunogen, Merck, Mersana, and Myriad.
Melinda Telli, MD—has disclosed that she is a consultant for Merck, Pfizer and Tesaro. Her institution receives grant/research support from Abbvie, Pfizer and Tesaro.

Presenters
Floor J. Backes, MD—has disclosed that she is a consultant for Clovis and Tesaro. She receives grant/research support from Clovis.
Beth Y. Karlan—has disclosed that she is a consultant and speaker for Invitae. She receives grant/research support from AstraZeneca and Tesaro.
Ursula Matulonis, MD—has disclosed that she is a consultant for 2X Oncology, FUJIFILM, Geneos, Immunogen, Merck, Mersana, and Myriad.
Bradley J. Monk—has disclosed that he is a consultant for Abbvie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis, Genmab, Gradalis, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Mateon, Merck, Myriad, Perthera, Pfizer, Precison Oncology, Puma, Roche/Genentech, Samumed, Takeda, Tesaro, Inc., and VBL. He also is a member of the speakers’ bureaus for AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, and Tesaro, Inc.
Pamela Munster, MD—disclosures to come.
Bobbie J. Rimel–has disclosed that she is a consultant for AstraZeneca, Clovis, Genentech, and Tesaro.
Angeles Alvarez Secord, MD—has disclosed that she is a consultant for Alexion, Aravive, AstraZeneca, Clovis and Janssen/Johnson&Johnson. She also receives grant/research support from AbbVie, Amgen, Astellas Pharma Inc., and Astex.
Melinda Telli, MD—has disclosed that she is a consultant for Merck, Pfizer and Tesaro. Her institution receives grant/research support from Abbvie, Pfizer and Tesaro.
Robert M. Wenham, MD, MS, FACOG, FACS—has disclosed that he is a consultant for Clovis, Genentech, Mersana Therapeutics, Inc., and TESARO, Inc. He receives grant/research support from Merck. He also is a member of the speakers’ bureaus for Clovis, Genentech, and TESARO, Inc.

Reviewers
Gabriela Lacatus, RN, BSN, OCN, PhD—has no relevant financial relationships to disclose in relation to the content of this activity.
Megan May, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.
Shannon N. Westin, MD, MPH—has no relevant financial relationships to disclose in relation to the content of this activity.